Numerous studies have demonstrated that CTRP9 has anti-inflammatory properties and modulates inflammatory responses, thereby attenuating EC dysfunction in PAH.196,197 Over-expression of CTRP9 significantly mitigates inflammation, apoptosis, and ECM accumulation in PAH by activating the Akt pathway.198. Here, C1QTNF9 is linked to pulmonary arterial hypertension.